May 26, 2024iMetaOpen Access

The feasibility of using pathobiome strains as live biotherapeutic products for human use

View Full Paper

Ask AI

Bookmark

Pathobiome strains offer viable templates for live biotherapeutic products when evaluated at the strain level, depending on specific functional genes and host microenvironments.
Analysis of 25 intestinal bacterial strains across multiple drugs identified 29 distinct interactions, showing that gut microbiota alter drug bioavailability and therapeutic efficacy.
Strategic development calls for whole-genome screening and recombinant live biotherapeutics, mitigating risks of horizontal gene transfer while delivering active metabolites safely.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Review demonstrates that gut pathobiome strains hold therapeutic utility when assessed at the strain level, highlighting strategies to balance microbial efficacy and clinical safety.

Cite This Study

Jin et al. (2024) studied this question.

synapsesocial.com/papers/68e6859fb6db64358760e8a9 https://doi.org/10.1002/imt2.202

View Full Paper

Ask AI

Bookmark

Implication

Review demonstrates that gut pathobiome strains hold therapeutic utility when assessed at the strain level, highlighting strategies to balance microbial efficacy and clinical safety.

The feasibility of using pathobiome strains as live biotherapeutic products for human use

Key Points

Discussion

Implication

Cite This Study

The feasibility of using pathobiome strains as live biotherapeutic products for human use

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider